Abstract
Parenteral delivery of long-acting glucagon-like peptide-1 (GLP-1) mimetics has received much attention as a therapeutic option for diabetes. However, cell therapy-based GLP-1 treatments may provide a more physiological regulation of blood glucose. The present study assessed the effects of chronic GLP-1 delivery by cell therapy, using the GLP-1-secreting GLUTag cell line, in normoglycemic and streptozotocin-induced diabetic mice. GLUTag cell aggregates were transplanted into the subscapular region of mice. Over 30 days, cellular transplantation gave rise to encapsulated and well-vascularized growths, which contained immunoreactive GLP-1. Cell implantation was well tolerated and had no appreciable metabolic effects in normal mice. However, transplantation significantly (P
| Original language | English |
|---|---|
| Pages (from-to) | 1077-1084 |
| Journal | Gene Therapy |
| Volume | 20 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 1 Nov 2013 |
Fingerprint Dive into the research topics of 'Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice'. Together they form a unique fingerprint.
Cite this
Vasu, S., Moffett, RC., McCluskey, J., Hamid, MH., Irwin, N., & Flatt, P. (2013). Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice. Gene Therapy, 20(11), 1077-1084. https://doi.org/10.1038/gt.2013.33